Cowen and Company set a $3.00 price target on Alimera Sciences, Inc. (NASDAQ:ALIM) in a research note released on Thursday, August 3rd. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued reports about the stock. HC Wainwright set a $5.00 target price on shares of Alimera Sciences and gave the company a buy rating in a research report on Friday, August 4th. Rodman & Renshaw began coverage on shares of Alimera Sciences in a research report on Thursday, April 27th. They issued a buy rating and a $4.00 target price on the stock. Zacks Investment Research upgraded shares of Alimera Sciences from a hold rating to a buy rating and set a $1.50 price target for the company in a research note on Monday, July 10th. Finally, ValuEngine upgraded shares of Alimera Sciences from a sell rating to a hold rating in a research note on Thursday, July 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $3.38.

Alimera Sciences (NASDAQ:ALIM) opened at 1.51 on Thursday. The company’s 50-day moving average price is $1.46 and its 200-day moving average price is $1.40. Alimera Sciences has a one year low of $1.03 and a one year high of $1.77. The stock’s market cap is $98.88 million.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $10.40 million during the quarter, compared to analysts’ expectations of $10.20 million. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.17) earnings per share. Analysts forecast that Alimera Sciences will post ($0.21) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Alimera Sciences, Inc. (NASDAQ:ALIM) PT Set at $3.00 by Cowen and Company” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/15/alimera-sciences-inc-nasdaqalim-given-a-3-00-price-target-at-cowen-and-company-updated.html.

Several hedge funds have recently added to or reduced their stakes in ALIM. KCG Holdings Inc. boosted its stake in Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares during the period. PNC Financial Services Group Inc. boosted its stake in Alimera Sciences by 24.3% in the second quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 35,200 shares during the period. Kennedy Capital Management Inc. purchased a new stake in Alimera Sciences during the first quarter valued at approximately $467,000. Finally, JW Asset Management LLC boosted its stake in Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares during the period. Institutional investors own 43.77% of the company’s stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Stock Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related stocks with our FREE daily email newsletter.